Investors are starting to appreciate the business potential of vaccines

Investors are starting to appreciate the business potential of vaccines
·4 min read

Pfizer reported revenue of $3.5 billion from its vaccine in the first quarter of 2021. Moderna sold $1.7 billion worth of vaccines in the same period, turning a profit for the first time in the company’s history. BioNTech, which is making the vaccine in partnership with Pfizer, expects $15 billion in vaccine sales this year (with an expected profit above 25%).

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting